PRELIMINARY RESULTS OF THE EARLY USE OF CORTICOSTEROIDS WITH AXICABTAGEN CILOLEUCEL (AXI-CEL) IN PATIENTS DIAGNOSED WITH RELAPSED/REFRACTORY LARGE B CELL LYMPHOMA (R/R LBCL)

被引：0
|
作者：
Max, Topp S. [1 ]
Van Meerten, T. [2 ]
Wermke, M.
Pieternella, Lugtenburg J. [3 ]
Monique, Minnema C. [4 ]
Kevin, Song W. [5 ]
Thieblemont, C.
Jiang, Y. [6 ]
Plaks, V [7 ]
Kerber, A. [8 ]
Kersten, M. J. [8 ]
机构：
[1] Univ Klinikum Wurzburg, Med Klin & Poliklin 2, Wurzburg, Germany
[2] Univ Med Ctr Groningen, Groningen, Netherlands
[3] Univ Hosp Carl Gustav Carus, Dresden, Germany
[4] Erasmus MC, Lunenburg Lymphoma Phase 1 2 Consortium HOVON LLP, Rotterdam, Netherlands
[5] Univ Med Ctr Utrecht, Utrecht, Netherlands
[6] Univ British Columbia, Vancouver, BC, Canada
[7] Hop St Louis, Paris, France
[8] Kite, Santa Monica, CA USA
来源：
HAEMATOLOGICA | 2019年 / 104卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
CO-132
引用
收藏
页码：98 / 98
页数：1
相关论文
共 50 条
  • [21] DURABILITY OF ANSWERS IN THE ZUMA-1, PIVOTAL STUDY PHASE 2 OF AXICABTAGEN CILOLEUCEL (AXI-CEL) IN PATIENTS WITH LARGE CELL LYMPHOMA B REFRACTORY
    Locke, F. L.
    Ghobadi, A.
    Jacobson, C. A.
    Jacobsen, E.
    Miklos, D. B.
    Lekakis, L. J.
    Braunschweig, I
    Oluwole, O. O.
    Lin, Y.
    Siddiqi, T.
    Deol, A.
    Reagan, P. M.
    Farooq, U.
    Bot, A.
    Jiang, Y.
    Rossi, J. M.
    Xue, A.
    Go, W. Y.
    Neelapu, Sattva S.
    HAEMATOLOGICA, 2018, 103 : 95 - 96
  • [22] RESULTS BY PRIOR LOT IN ZUMA-1, PIVOTAL STUDY PHASE 1/2 OF AXICABTAGEN CILOLEUCEL (AXI-CEL) IN PATIENTS WITH LARGE CELL LYMPHOMA B REFRACTORY
    Locke, F. L.
    Ghobadi, A.
    Lekakis, L. J.
    Miklos, D. B.
    Jacobson, C. A.
    Jacobsen, E.
    Braunschweig, I
    Oluwole, O. O.
    Siddiqi, T.
    Lin, Y.
    Reagan, P. M.
    Farooq, U.
    Deol, A.
    Bot, A.
    Rossi, J. M.
    Jiang, Y.
    Xue, A.
    Go, W. Y.
    Neelapu, S. S.
    HAEMATOLOGICA, 2018, 103 : 96 - 96
  • [23] Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): 2-Year Follow-up of ZUMA-1 Cohort 6
    Oluwole, Olalekan O.
    Forcade, Edouard
    Munoz, Javier
    de Guibert, Sophie
    Vose, Julie M.
    Bartlett, Nancy L.
    Lin, Yi
    Deol, Abhinav
    McSweeney, Peter A.
    Goy, Andre H.
    Kersten, Marie Jose
    Jacobson, Caron A.
    Farooq, Umar
    Minnema, Monique C.
    Thieblemont, Catherine
    Timmerman, John
    Stiff, Patrick
    Avivi, Irit
    Tzachanis, Dimitrios
    Zheng, Yan
    Vardhanabhuti, Saran
    Nater, Jenny
    Shen, Rhine R.
    Miao, Harry
    Kim, Jenny
    van Meerten, Tom
    BLOOD, 2022, 140 : 10399 - 10401
  • [24] Long-Term Efficacy and Immune Reconstitution with Bendamustine As a Lymphodepleting Agent for Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory or Relapsed Large B-Cell Lymphoma (LBCL)
    Bharadwaj, Sushma
    Lau, Eric
    Goyal, Anmol
    Hamilton, Mark P.
    Srinagesh, Hrishikesh
    Jensen, Alexandria
    Syal, Shriya
    Mallampet, Jayasindhu
    Latchford, Theresa
    Sahaf, Bita
    Weng, Wen-Kai
    Smith, Melody
    Maecker, Holden T.
    Frank, Matthew J.
    Miklos, David B.
    Dahiya, Saurabh
    BLOOD, 2023, 142
  • [25] Retreatment of Patients With Refractory Large B Cell Lymphoma With Axicabtagene Ciloleucel (Axi-Cel) in ZUMA-1
    Locke, Frederick
    Bartlett, Nancy
    Jacobson, Caron
    Oluwole, Olalekan
    Munoz, Javier
    Lekakis, Lazaros
    Topp, Max
    Avivi, Irit
    Kim, Jenny
    Chu, Rong
    Zheng, Lianqing
    Rossi, John
    Bot, Adrian
    Neelapu, Sattva
    AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 : S21 - S22
  • [26] Primary Analysis of ZUMA7: A Phase 3 Randomized Trial of Axicabtagene Ciloleucel (Axi-Cel) versus StandardofCare (SOC) Therapy in Patients (Pts) with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)
    Ghobadi, Armin
    Locke, Frederick L.
    Miklos, David B.
    Jacobson, Caron A.
    Perales, Miguel-Angel
    Kersten, Marie Jose
    Oluwole, Olalekan O.
    Rapoport, Aaron P.
    McGuirk, Joseph P.
    Pagel, John M.
    Munoz, Javier
    Farooq, Umar
    van Meerten, Tom
    Reagan, Patrick M.
    Sureda, Anna
    Flinn, Ian W.
    Vandenberghe, Peter
    Song, Kevin W.
    Dickinson, Michael
    Minnema, Monique C.
    Riedell, Peter A.
    Leslie, Lori A.
    Chaganti, Sridhar
    Yang, Yin
    Filosto, Simone
    Schupp, Marco
    To, Christina
    Cheng, Paul
    Gordon, Leo I.
    Westin, Jason R.
    MOLECULAR THERAPY, 2022, 30 (04) : 519 - 519
  • [27] Matching-Adjusted Indirect Comparison (MAIC) of Axicabtagene Ciloleucel (Axi-Cel) and Lisocabtagene Maraleucel (Liso-Cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) After Two or More Prior Lines of Therapy
    Oluwole, Olalekan O.
    Chen, Jenny M. H.
    Chan, Keith
    Patel, Anik R.
    Jansen, Jeroen P.
    Keeping, Sam
    Bashir, Zahid
    Zheng, Yan
    Snider, Julia
    Locke, Frederick L.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S388 - S388
  • [28] Analysis of PET-CT Derived Radiomic Biomarkers with Efficacy, Safety, and Expansion of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL)
    Bharadwaj, Sushma
    Lau, Eric
    Hashmi, Ayesha
    Hamilton, Mark P.
    Jensen, Alexandria
    Goyal, Anmol
    Marar, Mallika
    Lee, Caroline
    Ananth, Snegha
    Sahaf, Bita
    Mallampet, Jayasindhu
    Ehlinger, Zachary
    Syal, Shriya
    Patil, Sunita
    Guo, Henry
    Smith, Melody
    Weng, Wen-Kai
    Frank, Matthew J.
    Binkley, Michael S.
    Miklos, David B.
    Dahiya, Saurabh
    BLOOD, 2023, 142
  • [29] ZUMA-7: RANDOMIZED PHASE 3 ESSAY OF AXICABTAGEN CILOLEUCEL (AXI-CEL) VS STANDARD TREATMENT (SOC) IN PATIENTS WITH LYMPHOMA B DIFFUSE OF LARGE CELLS IN RECYCLED/REFRACTORY (R/R DLBCL)
    Caballero, M. D.
    Cwynarski, K.
    Dreger, P.
    Thieblemont, C.
    Vandenberghe, P.
    Zinzani, P. L.
    Mueller, A.
    Greinix, H.
    Avivi, I
    Enblad, G.
    Locke, F. L.
    Yang, Y.
    Brock, K.
    Cheng, P.
    Kersten, M. J.
    HAEMATOLOGICA, 2018, 103 : 359 - 359
  • [30] Retreatment (reTx) of Patients with Refractory Large B Cell Lymphoma with Axicabtagene Ciloleucel (Axi-Cel) in ZUMA-1
    Locke, Frederick L.
    Bartlett, Nancy L.
    Jacobson, Caron A.
    Oluwole, Olalekan O.
    Munoz, Javier
    Lekakis, Lazaros J.
    Topp, Max S.
    Avivi, Irit
    Kim, Jenny J.
    Chu, Rong
    Zheng, Lianqing
    Rossi, John M.
    Bot, Adrian
    Neelapu, Sattva S.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S265 - S265
12345